Table 4.
Infliximab discontinuation | Retransitioned due to objective markers (n = 4) | Retransitioned due to symptoms only (n = 9) |
---|---|---|
Discontinuing infliximab with switch to other biological treatment | 1 (25.0%) | 4 (44.5%) |
Discontinuing infliximab without switch | 3 (75.0%) | 5 (55.5%) |